Patents Assigned to Santen Pharmaceutical Co. Ltd.
  • Patent number: 9089720
    Abstract: The present invention provides a new pharmaceutical application of a 15,15-difluoroprostaglandin F2? derivative. As a result of intensive studies in order to find a new pharmaceutical application of a 15,15-difluoroprostaglandin F2? derivative, it was found that, in a European Phase III clinical trial for tafluprost, one of the 15,15-difluoroprostaglandin F2? derivatives, with patients with open-angle glaucoma or ocular hypertension, tafluprost has actions of growing eyelashes, making eyelashes thicker, and changing the color thereof, that is, has an effect of promoting the growth of hair (eyelashes). Therefore, a 15,15-difluoroprostaglandin F2? derivative is useful as a hair growth promoting agent, and is expected to be useful as an active ingredient of a preventive or therapeutic agent for a disease associated with hair such as alopecia and a hair care product or a hair cosmetic product for regrowing hair, growing hair, increasing hair density, nourishing hair, or the like.
    Type: Grant
    Filed: September 4, 2009
    Date of Patent: July 28, 2015
    Assignees: SANTEN PHARMACEUTICAL CO., LTD., ASAHI GLASS COMPANY, LIMITED
    Inventor: Auli Ropo
  • Publication number: 20150196541
    Abstract: Provided is a pharmaceutical preparation for treatment or prevention of glaucoma or ocular hypertension, comprising 0.0003 to 0.01% (w/v) of isopropyl(6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate, or a salt thereof.
    Type: Application
    Filed: January 8, 2015
    Publication date: July 16, 2015
    Applicant: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Naveed Shams, Henk-Andre Kroon, Hisashi Kawata, Noriko Kawabata
  • Patent number: 9062061
    Abstract: A compound represented by the following general formula (1) or a salt thereof. R1 represents a halogen atom and so on; R2 and R3 each represent a hydrogen atom and so on; R4 and R5 each represent a hydrogen atom and so on, or R4 and R5 may form an oxo group; Ra and Rb each represent a lower alkyl group optionally having a substituent and so on, or they may bind to each other to form a nitrogen-containing heterocyclic ring which may be substituted by one or plural Rc; Rc represents an aryl group optionally having a substituent and so on; ring A represents a benzene ring and so on; and m represents 0, 1 or 2.
    Type: Grant
    Filed: July 12, 2012
    Date of Patent: June 23, 2015
    Assignee: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Takahiro Honda, Hiroshi Enomoto, Kenji Kawashima, Shinji Takaoka, Yasutaka Fujioka, Mamoru Matsuda, Koji Ohashi, Yukie Fujita, Shin-ichiro Hirai, Hiroaki Kurashima
  • Patent number: 9029572
    Abstract: A method of manufacturing a compound or a salt thereof expressed with a formula (III) below, characterized by causing a compound or a salt thereof expressed with a formula (I) below and a compound or a salt thereof expressed with a formula (II) below to react in the presence of carbonate and copper salt or in the presence of hydroxide salt, carbonate, and copper salt.
    Type: Grant
    Filed: June 13, 2014
    Date of Patent: May 12, 2015
    Assignee: Santen Pharmaceutical Co., Ltd.
    Inventors: Kazuhiro Kudou, Noriyoshi Yamamoto, Masakazu Ban, Atsushi Ohno
  • Patent number: 9029398
    Abstract: In the course of developing 2-[[[2-[(hydroxyacetyl)amino]-4-pyridinyl]methyl]thio]-N-[4-(trifluoromethoxy)phenyl]-3-pyridinecarboxamide (compound A), there are the multiple problems: 1) compound A or its salt is difficult to be recrystallized, the storage stability largely differs depending on the kind of the salt, and it is very difficult to obtain a salt of compound A having excellent storage stability; 2) in a crystallization process of compound A, it is very difficult to control a crystal polymorph, and 3) compound A (free body) causes mineral deposition in the stomach when it is orally administered repeatedly.
    Type: Grant
    Filed: July 16, 2010
    Date of Patent: May 12, 2015
    Assignee: Santen Pharmaceutical Co., Ltd.
    Inventors: Masashi Niwa, Hiroshi Deguchi
  • Publication number: 20150125395
    Abstract: A method for changing a condition of an eyelid of a mammal excluding a human, a model animal for evaluating a therapeutic or prophylactic effect against an eyelid disease obtained by the method, a method for producing the model animal, a method of screening using the model animal and a substance having a therapeutic or prophylactic effect against an eyelid disease selected by the method of screening, and a therapeutic or prophylactic agent against an eyelid disease containing the substance as an active ingredient.
    Type: Application
    Filed: June 18, 2013
    Publication date: May 7, 2015
    Applicant: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Hideki Miyake, Tomoko Oda
  • Publication number: 20150125394
    Abstract: A method for changing a condition of an eyelid of a hairless animal, a model animal for evaluating a therapeutic or prophylactic effect against an eyelid disease obtained by the method, a method for producing the model animal, a method of screening using the model animal and a substance having a therapeutic or prophylactic effect against an eyelid disease selected by the method of screening, and a therapeutic or prophylactic agent against an eyelid disease containing the substance as an active ingredient.
    Type: Application
    Filed: June 18, 2013
    Publication date: May 7, 2015
    Applicant: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Hideki Miyake, Tomoko Oda
  • Patent number: 9006208
    Abstract: An agent for treatment of dry eye comprising a combination of a P2Y2 receptor agonist at a therapeutically effective concentration and hyaluronic acid or a salt thereof at a therapeutically effective concentration, which agent has a dosage form of an ophthalmic agent, can promote the secretion of tear remarkably and can improve corneal epithelial disorders remarkably, and is therefore expected to be a novel agent for treatment of dry eye.
    Type: Grant
    Filed: September 9, 2011
    Date of Patent: April 14, 2015
    Assignee: Santen Pharmaceutical Co., Ltd.
    Inventors: Yuko Shichijo, Atsuyoshi Dota, Takashi Nagano, Masatsugu Nakamura, Asuka Sakamoto
  • Publication number: 20150073005
    Abstract: To provide a composition for hair growth (hair growth agent) which has high hair growing effects and can be used for prevention or treatment of alopecia. The composition for hair growth comprises as an active ingredient at least one member selected from the group consisting of a compound represented by the formula (1) and a salt thereof. In the formula, R is a carboxy group or an alkoxycarbonyl group.
    Type: Application
    Filed: November 17, 2014
    Publication date: March 12, 2015
    Applicants: ASAHI GLASS COMPANY, LIMITED, SANTEN PHARMACEUTICAL, CO., LTD.
    Inventors: Atsushi Shimazaki, Arata Yasuda, Yasushi Matsumura
  • Patent number: 8975256
    Abstract: A 1,2,3,4-tetrahydroquinoxaline compound represented by the following formula: In the formula (1), R1 represents substituents such as a halogen, an alkyl, a cycloalkyl, an aryl or a heterocyclic group; p represents 0 to 5; R2 represents substituents such as a halogen, an alkyl, a hydroxyl or an alkoxy group; q represents 0 to 2; R3 represents substituents such as hydrogen, an alkyl, an alkenyl, an alkylcarbonyl or an arylcarbonyl group; R4 and R5 independently represent substituents such as hydrogen, a halogen, an alkyl, an alkenyl, an alkynyl, a cycloalkyl, an aryl or a heterocyclic group; R6 represents substituents such as hydrogen, an alkyl, an alkenyl, an alkynyl, a cycloalkyl, an aryl or a heterocyclic group; A represents an alkylene; R7 represents OR8, NR8R9, SR8, S(O)R8, S(O)2R8; R8 and R9 independently represent substituents such as hydrogen, an alkyl or an alkenyl; and X represents O or S.
    Type: Grant
    Filed: July 9, 2013
    Date of Patent: March 10, 2015
    Assignee: Santen Pharmaceutical Co., Ltd.
    Inventors: Mamoru Matsuda, Toshiyuki Mori, Kenji Kawashima, Minoru Yamamoto, Masatomo Kato, Miwa Takai, Masato Nagatsuka, Sachiko Kobayashi
  • Patent number: 8940045
    Abstract: An intraocular lens comprises an optic and at least two haptics, each of which comprises a step feature that protrudes from a posterior surface of the haptic to prevent posterior capsular opacification.
    Type: Grant
    Filed: November 24, 2010
    Date of Patent: January 27, 2015
    Assignee: Santen Pharmaceutical Co., Ltd.
    Inventors: Anand Doraiswamy, Jensen Buck, Daniel Hamilton
  • Publication number: 20150011518
    Abstract: A drug-dissolved non-aqueous liquid composition containing a drug, dioleylphosphatidylcholine, tocopherol and an organic solvent, wherein the blend concentration ratio between the dioleylphosphatidylcholine and the tocopherol falls within the range of 75/25 to 25/75, the blend concentration of the dioleylphosphatidylcholine falls within the range of 15 to 85% (w/w), the blend concentration of the tocopherol falls within the range of 15 to 85% (w/w), and the phase of the non-aqueous liquid composition changes into a non-lamellar liquid crystal upon contact with water, a phosphate buffer, a body fluid, a lacrimal fluid or a vitreous fluid.
    Type: Application
    Filed: January 30, 2013
    Publication date: January 8, 2015
    Applicant: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Kazuhito Yamada, Arto Urtti, Mechthild Burmester
  • Patent number: 8927005
    Abstract: Described herein are liquid formulations which deliver a variety of therapeutic agents, including but not limited to rapamycin, to a subject for an extended period of time; liquid formulations which form a non-dispersed mass when placed in an aqueous medium of a subject; liquid formulations, comprising a therapeutic agent and a plurality of polymers; and methods for delivering therapeutic agents to a subject for an extended period of time using the liquid formulations. The liquid formulation may be placed in an aqueous medium of a subject, including but not limited to via intraocular or periocular administration. A method may be used to administer rapamycin to treat or prevent angiogenesis, choroidal neovascularization, or age-related macular degeneration in a subject.
    Type: Grant
    Filed: January 14, 2013
    Date of Patent: January 6, 2015
    Assignee: Santen Pharmaceutical Co., Ltd.
    Inventors: Sreenivasu Mudumba, Philippe J M Dor, Thierry Nivaggioli, David A. Weber, Sidiq Farooq
  • Publication number: 20140371459
    Abstract: Provided is a method for producing a compound represented by formula (7) or a salt thereof: the method comprising the steps of: removing a R1 group and a R2 group from a compound represented by formula (5) or a salt thereof: and reacting the compound (in which R1 and R2 in formula (5) are hydrogen atoms) obtained in the removing step or a salt thereof with a compound represented by formula (d): or a salt thereof in the presence of a base. The method is a method for producing a 1,2-dihydroquinoline derivative having glucocorticoid receptor binding activity or a salt thereof. This method does not require a purification step by column chromatography and is suitable for industrial production.
    Type: Application
    Filed: January 21, 2013
    Publication date: December 18, 2014
    Applicants: SANTEN PHARMACEUTICAL CO., LTD., KYOWA HAKKO BIO CO., LTD.
    Inventors: Noriyoshi Yamamoto, Atsushi Ohno, Kazuhiro Kudou, Masakazu Ban, Takashi Mimura, Takashi Ohtani
  • Patent number: 8901155
    Abstract: A method for treating a TRPV1-mediated disease by administering to a patient a therapeutically effective amount of a compound or a salt thereof having the following formula [I]: wherein A represents a lower alkylene group or a lower alkenylene group; R1 represents a hydrogen atom, an unsubstituted or substituted alkyl group or an unsubstituted or substituted alkenyl group; and R2 and R3 are the same or different and represent a hydrogen atom, an unsubstituted lower alkyl group or a lower alkyl group substituted by a monocyclic cycloalkyl group, a polycyclic cycloalkyl group or an aryl group.
    Type: Grant
    Filed: November 19, 2012
    Date of Patent: December 2, 2014
    Assignee: Santen Pharmaceutical Co., Ltd.
    Inventors: Kenji Oki, Fumio Tsuji, Chikako Setoguchi, Iwao Seki, Masaaki Murai, Minoru Sasano
  • Patent number: D721580
    Type: Grant
    Filed: September 17, 2013
    Date of Patent: January 27, 2015
    Assignee: Santen Pharmaceutical Co., Ltd.
    Inventors: Hiroshi Yamada, Tsuyoshi Kakiuchi
  • Patent number: D721959
    Type: Grant
    Filed: September 17, 2013
    Date of Patent: February 3, 2015
    Assignee: Santen Pharmaceutical Co., Ltd.
    Inventors: Hiroshi Yamada, Tsuyoshi Kakiuchi
  • Patent number: D724430
    Type: Grant
    Filed: June 30, 2014
    Date of Patent: March 17, 2015
    Assignee: Santen Pharmaceutical Co., Ltd.
    Inventors: Yoshitaka Tahara, Yoshiyuki Azuma, Tsuyoshi Kakiuchi, Hiroshi Yamada
  • Patent number: D728789
    Type: Grant
    Filed: July 15, 2013
    Date of Patent: May 5, 2015
    Assignee: Santen Pharmaceutical Co., Ltd.
    Inventors: Anand Doraiswamy, Jensen Buck, Daniel Hamilton
  • Patent number: D729390
    Type: Grant
    Filed: July 15, 2013
    Date of Patent: May 12, 2015
    Assignee: Santen Pharmaceutical Co., Ltd.
    Inventors: Anand Doraiswamy, Jensen Buck, Daniel Hamilton